High dose oral formulation of bisphosphonate and a process...

Details High dose oral formulation of bisphosphonate and a process... High dose oral formulation of bisphosphonate and a process...

2011-04-12

2011-04-12

Tran, S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S464000

Reexamination Certificate

active

07923028

ABSTRACT:
The invention relates to a high dose oral formulation of bisphosphonates and to a process for the preparation of such formulations.

REFERENCES:
patent: 3962432 (1976-06-01), Schmidt-Dünker
patent: 4054598 (1977-10-01), Blum et al.
patent: 4073838 (1978-02-01), Barnickel et al.
patent: 4267108 (1981-05-01), Blum et al.
patent: 4327039 (1982-04-01), Blum et al.
patent: 4407761 (1983-10-01), Blum et al.
patent: 4621077 (1986-11-01), Rosini et al.
patent: 4624947 (1986-11-01), Blum et al.
patent: 4666895 (1987-05-01), Bosies et al.
patent: 4705651 (1987-11-01), Staibano
patent: 4711880 (1987-12-01), Stahl et al.
patent: 4719203 (1988-01-01), Bosies et al.
patent: 4746654 (1988-05-01), Breliere et al.
patent: 4761406 (1988-08-01), Flora et al.
patent: 4777163 (1988-10-01), Bosies et al.
patent: 4812311 (1989-03-01), Uchtman
patent: 4876248 (1989-10-01), Beliere et al.
patent: 4922007 (1990-05-01), Kieczykowski et al.
patent: 4927814 (1990-05-01), Gall et al.
patent: 4939130 (1990-07-01), Jaeggi et al.
patent: 4970335 (1990-11-01), Isomura et al.
patent: 4971958 (1990-11-01), Bosies et al.
patent: 5002937 (1991-03-01), Bosies et al.
patent: 5018651 (1991-05-01), Hull et al.
patent: 5019651 (1991-05-01), Kieczkowski
patent: 5206253 (1993-04-01), Bosies et al.
patent: 5344825 (1994-09-01), Khanna et al.
patent: 5348748 (1994-09-01), Sheth et al.
patent: 5356887 (1994-10-01), Brenner
patent: 5358941 (1994-10-01), Bechard et al.
patent: 5431920 (1995-07-01), Bechard
patent: 5462932 (1995-10-01), Brenner et al.
patent: 5488041 (1996-01-01), Barbier et al.
patent: 5882656 (1999-03-01), Bechard et al.
patent: 5994329 (1999-11-01), Daifotis et al.
patent: 6123964 (2000-09-01), Asgharnejad et al.
patent: 6124314 (2000-09-01), Cameron et al.
patent: 6143326 (2000-11-01), Mockel et al.
patent: 6165513 (2000-12-01), Dansereau et al.
patent: 6294196 (2001-09-01), Gabel et al.
patent: 6419955 (2002-07-01), Gabel et al.
patent: 6432932 (2002-08-01), Daifotis et al.
patent: 6468559 (2002-10-01), Chen et al.
patent: 6544967 (2003-04-01), Daifotis et al.
patent: 6573252 (2003-06-01), Del Soldato
patent: 6638920 (2003-10-01), Thompson
patent: 6680307 (2004-01-01), Bauss et al.
patent: 6692764 (2004-02-01), Katdare et al.
patent: 6699850 (2004-03-01), Reszka et al.
patent: 6770289 (2004-08-01), Uria
patent: 6838584 (2005-01-01), Blizzard et al.
patent: 6991806 (2006-01-01), Dickinson et al.
patent: 7008640 (2006-03-01), Watanabe et al.
patent: 2001/0051616 (2001-12-01), Karpf et al.
patent: 2002/0006441 (2002-01-01), Gabel et al.
patent: 2003/0118634 (2003-06-01), Schofield et al.
patent: 2003/0139378 (2003-07-01), Daifotis et al.
patent: 2003/0175340 (2003-09-01), McCallister et al.
patent: 2003/0195171 (2003-10-01), Daifotis et al.
patent: 2003/0225039 (2003-12-01), Bauss et al.
patent: 2004/0087550 (2004-05-01), Zanetti et al.
patent: 2004/0097469 (2004-05-01), Little et al.
patent: 2004/0147484 (2004-07-01), Boyd et al.
patent: 2005/0070504 (2005-03-01), Burgio, Jr. et al.
patent: 2308532 (2000-12-01), None
patent: 2149052 (2003-03-01), None
patent: 336 298 (1989-10-01), None
patent: 558 913 (1993-09-01), None
patent: 1135140 (2005-08-01), None
patent: 2797185 (2001-09-01), None
patent: 2 153 225 (1985-08-01), None
patent: WO 90/00798 (1990-01-01), None
patent: WO 9412200 (1994-06-01), None
patent: WO 96/09056 (1996-03-01), None
patent: WO 96/17616 (1996-06-01), None
patent: WO 97/15191 (1997-05-01), None
patent: WO 97/39755 (1997-10-01), None
patent: WO 99/09995 (1999-03-01), None
patent: WO 00/21450 (2000-04-01), None
patent: WO 00/21541 (2000-04-01), None
patent: WO 00/61111 (2000-10-01), None
patent: WO 01/01991 (2001-01-01), None
patent: WO 0101991 (2001-01-01), None
patent: WO 01/15703 (2001-03-01), None
patent: WO 01/76592 (2001-10-01), None
patent: WO 01/89494 (2001-11-01), None
patent: WO 01/89494 (2001-11-01), None
patent: WO 01/97788 (2001-12-01), None
patent: WO 01/97788 (2001-12-01), None
patent: WO 02/00204 (2002-01-01), None
patent: WO 02/03976 (2002-01-01), None
patent: WO 03/095029 (2003-11-01), None
patent: WO 2004/067063 (2004-08-01), None
Ringe et al., Rheumatology (Oxford), 42(6):743-9 (2003) (PMID:12730532 Abstract).
Schimmer et al., Clin Ther., 25(1):19-34 (2003) (PMID:12637110 Abstract).
Body et al., Support Care Cancer, 10(5):399-407 (2002) (PMID:12136223 Abstract).
Bergner et al., Nephrol Dial Transplant, 17(7):1281-5 (2002) (PMID:12105253 Abstract).
Body et al., J. Clin. Oncol.,16(12):3890-9 (1998) (PMID:9850035 Abstract).
Mazess, Lunar News, pp. 1 and 23 (1996).
Mazess, Lunar News, pp. 1 and 31 (1996).
Quimby et al., J. Org. Chem., 32, pp. 4111-4114 (1967).
Rus, B.J., et al ,J. of Bone and Mineral Res., (2001) 16(10), pp. 1871-1878.
Delmas, P.D. et al, Calcified Tissue Intern (2003) 72(4), p. 332.
Chapurlat, R.D., et al, Expert Opinion on Pharmacotherapy, England (2003) 4(3), pp. 391-396.
Hyldstrup et al., Calcif Tissue Int., 53, pp. 297-300 (1993).
Nies, A.S., and Spielberg, S.P., Principles of Therapeutics, In Hardman, J.G., and L.E. Limbird (Eds.), Goodman & Gilman's the pharmacological basis of therapeutics, ninth edition, pp. 43-62, New York: McGraw-Hill (1996).
Bauss, et al., J. Rheumatol., 29, pp. 990-998 (2002).
Farmacia Remington, Chapter 76—Preformulation, 17 edition, 1987.
Giron, D., Journal of Thermal Analysis and Calorimetry, vol. 64, Budapest-2001, pp. 38.
Giron, D., Thermochimica Acta 248-1-59, Elsevier Science B.V., 1995, pp. 1-59.
Merck & Co., NJ, USA Merck Index 13th, 2001, No. 4899.
Pharmaceutical Dosage Forms, 2ndEdition, 1989, vol. 1, pp. 34.
Hyldstrup L et al,Calcified Tissue International, (1993) 53(5), 297-300.
Excerpt on “Cellulose”, Merck Index, 13thEdition, pp. 1977 (2001).
Excerpt on “Starch”, Merck Index, 13thEdition, pp. 8877, (2001).
Remington's Pharmaceutical Sciences, 18thEdition (1990).
Teva Opposition to EP 1596870, May 8, 2008.
Generics Opposition to EP 1596870, May 8, 2008.
Synthon Opposition to EP 1596870, May 8, 2008.
Banker et al., Modern Pharmaceutics, 4thEd., pp. 293-312 (2002).
Remington, The Science and Practice of Pharmacy, 20thEd., pp. 860-869 (2000).
Banker et al., Modern Pharmaceutics, 4thEd., p. 320-322 (2002).
Excerpt on “Ibandronic Acid”, Merck Index, 14thEd. (2006).
Test Data, Nov. 3, 2006.
Excerpt on “Starch” and “Pregelatinized Starch”, Handbook of Pharmaceutical Excipients, 3d Edition, pp. 522, 528 (2000).
Gordon et al,Journal of Pharmaceutical Sciences, k82;2 (1993)220-226.
Merck Index 14thed, (2001) p. 337 “Cellulose”.
Banker G.S. et al,Modern Pharmaceutics, 4thed. (2002) 293-294, 297-298.
Remington: The Science and Practice of Pharmacy, 20thed. (2000) 860-865.
Sawbrick, J. et al,Encyclopedia of Pharmaceutical Technology, 2nded. (2002) p. 2721.

Affiliated with

Also associated with

Rating

High dose oral formulation of bisphosphonate and a process... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High dose oral formulation of bisphosphonate and a process..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High dose oral formulation of bisphosphonate and a process... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2706242